talimogene laherparepvec oncolytic virus
Selected indexed studies
- Talimogene Laherparepvec: An Oncolytic Virus Therapy for Melanoma. (Ann Pharmacother, 2017) [PMID:28351167]
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. (J Clin Oncol, 2015) [PMID:26014293]
- Oncolytic virus therapy: A new era of cancer treatment at dawn. (Cancer Sci, 2016) [PMID:27486853]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Talimogene Laherparepvec: An Oncolytic Virus Therapy for Melanoma. (2017) pubmed
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. (2015) pubmed
- Oncolytic virus therapy: A new era of cancer treatment at dawn. (2016) pubmed
- Oncolytic virotherapy. (2012) pubmed
- Therapy with oncolytic viruses: progress and challenges. (2023) pubmed
- Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival. (2024) pubmed
- Talimogene laherparepvec: First in class oncolytic virotherapy. (2018) pubmed
- Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy. (2015) pubmed
- New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy. (2024) pubmed
- Review of talimogene laherparepvec: A first-in-class oncolytic viral treatment of advanced melanoma. (2020) pubmed